BTG has announced that BGC20-1531, a novel EP4 receptor antagonist for the treatment of migraine headaches, will enter Phase IIa studies in H2 2009, with data anticipated in H2 2010.
If clinical proof of principle is demonstrated in these studies, BTG will seek development partners to conduct Phase IIb and subsequent studies.
In a clinical study recently presented at the 18th International Headache Research Symposium in Copenhagen, BTG demonstrated the effectiveness of BGC20-1531 as an analgesic in inflammatory and neurogenic pain induced in healthy volunteers.
The data from this study has improved confidence in the development of BGC20-1531 for treating migraines.
BTG licensed BGC20-1531 from Asterand in January 2006, completed pre-clinical development and entered the first Phase I trial in January 2008.
